

# ECCO CALL for participants to the ECCO Topical Review on Refractory IBD – what to do when everything fails? 2019-2020

#### **Context:**

Although the therapeutic arsenal in IBD is expanding, there is still a small proportion of patients who will be refractory to all approved drugs and that pose a challenge to the physician and surgeon alike. In these situations, a step-by-step approach to document the failure is needed, and "out of the box" therapies may be tried, along with close multi-disciplinary team working.

### Aim of the project:

The purpose of this Topical Review is to summarise the current knowledge and experience in multi-refractory IBD patients and to review the evidence behind various approaches, including the use of non-licensed medical options in the clinical scenario, as well as surgical options.

The lack of solid evidence and controversial data in multiple areas of this topic will be addressed by a high proportion of 'expert opinion' in this Topical Review:

- (1) by clearly pointing out 'opinion' versus 'evidence'
- (2) by using the rigorous standards and protocols comparable to the ones used for the ECCO Clinical Guidelines process - however summarised in the form of a Topical Review instead of a Clinical Guideline.

Analogous to the ECCO Consensus Guidelines, Workgroups prepare core messages as "Current Practice Positions" which will be discussed and, if deemed appropriate, will be voted on in a plenary meeting. After the final vote on the "Current Practice Positions", they are no longer amenable to change and the full manuscript is finalised for publication in the *Journal of Crohn's and Colitis* (JCC).

To facilitate the Consensus process, the ECCO participants will be selected for the Workgroups of this Topical Review on the basis of applications to this call.

**Seats for Y-ECCO Members are reserved and they are encouraged to apply** with an opportunity to be in charge of the systematic bibliographic review, the draft of the supporting text, and further development of e-Learning material.

### If you are:

- an ECCO Member (in good standing 2019 membership)
- and are interested in joining one of the Workgroups for this project

#### **Governing Board**

President Silvio Danese Italy

President-Elect Laurent Peyrin-Biroulet France

Past-Presiden Julián Panés Spain

Secretary
Willem Bemelman
The Netherlands

*Treasurer* Ailsa Hart United Kingdom

Education Officer James Lindsay United Kingdom

Scientific Officer Gerhard Rogler Switzerland

ECCO Office Ungargasse 6/13 1030 Vienna, Austria

Tel. +43-(0)1-710 22 42 Fax +43-(0)1-710 22 42-001 E-Mail ecco@ecco-ibd.eu www.ecco-ibd.eu

SWIFT GIBAATWWXXX IBAN AT5720111 28748039100

ATU 63674955 Austrian Register of Associations N° 468755685

DPR Number: N°4003204



able to commit to a mandatory face-to-face meeting at ECCO'20 Congress Vienna, February 12-15, 2019 (exact day and schedule TBC)

please send an e-mail to <a href="mailto:ecco@ecco-ibd.eu">ecco@ecco-ibd.eu</a> detailing:

- your name and affiliations;
- and a short (max. 10 lines) profile of yourself as an expert in the field.

# Deadline for submissions: June 30, 2019\*

\*Data processing consent and retention:

By sending an application by email to ecco@ecco-ibd.eu, you agree to the data processing for the above described project:

ECCO Office stores applicants' personal data of this application for the project timeframe. You have the right to object at any time at ecco@ecco-ibd.eu. ECCO Office will delete data securely after the end of this project.

# Topics and questions will be addressed in the following **Working Groups:**

# **WG1:** General considerations

- How should refractory disease be defined
- Risk factors and epidemiology of refractory disease
- Assessment of the reason for failure
- The importance of excluding concomitant clinical reasons behind treatment failure
- Possibility of "recycling" previously used drugs
- Consideration of clinical trials

# WG2: UC specific options

- Surgical considerations
- Unlicensed medical therapies
- Combining drugs with different MOA
- Management of post-surgical state/pouchitis

### WG3: CD specific options

- Surgical considerations
- Unlicensed medical therapies
- Combining drugs with different MOA
- Refractory perianal disease

#### ECCO is looking forward to your application!

On behalf of GuiCom

### **ECCO Office**

Ungargasse 6/13 1030 Vienna, Austria

Phone: +43-(0)1-710 22 42 +43-(0)1-710 22 42-001 Fax:

E-mail: ecco@ecco-ibd.eu URL: www.ecco-ibd.eu

#### **Governing Board**

President Silvio Danese Italy

President-Elect Laurent Peyrin-Biroulet France

Past-President Julián Panés Spain

Secretary

Willem Bemelman The Netherlands

Treasurer Ailsa Hart United Kingdom

**Education Officer** James Lindsay United Kingdom

Scientific Officer Gerhard Rogler Switzerland

CCO Office Ungargasse 6/13 1030 Vienna, Austria

+43-(0)1-710 22 42 +43-(0)1-710 22 42-001 E-Mail ecco@ecco-ibd.eu Url www.ecco-ibd.eu

SWIFT GIBAATWWXXX IBAN AT5720111 28748039100

63674955

Austrian Register of Associations N° 468755685

DPR Number: N°4003204